AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in ...

Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include ...

a Represents net earnings attributable to AbbVie Inc. Intangible asset impairment primarily reflects partial impairment charges related to the U.S. Imbruvica and CoolSculpting intangible assets.

Welcome to the AbbVie Fourth Quarter 2024 Earnings Conference ... impact from the Medicare Part D benefit redesign; Botox Therapeutics sales of $3.5 billion, total oral CGRP revenue of $2.1 ...

Relmada Therapeutics reported that interim analysis found that the Reliance II Phase 3 study is futile and is unlikely to meet the primary efficacy endpoint with statistical significance.

I am excited to share that Nimble is now part of AbbVie, a global leader in immunology ... and enhancing the clinical potential of our therapeutics. I’m thrilled to be part of this leading ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...